Abstract
Screening of the Amgen compound library led to the identification of 2-phenylamino-6-cyano-1H-benzimidazole 1a as a potent CK1 gamma inhibitor with excellent kinase selectivity and unprecedented CK1 isoform selectivity. Further structure-based optimization of this series resulted in the discovery of 1h which possessed good enzymatic and cellular potency, excellent CK1 isoform and kinase selectivity, and acceptable pharmacokinetic properties.
Copyright © 2012. Published by Elsevier Ltd.
MeSH terms
-
Animals
-
Benzimidazoles / chemistry*
-
Benzimidazoles / pharmacokinetics
-
Benzimidazoles / pharmacology*
-
Binding Sites
-
Casein Kinase I / antagonists & inhibitors*
-
Casein Kinase I / chemistry
-
Casein Kinase I / metabolism
-
Humans
-
Mice
-
Models, Molecular
-
Protein Isoforms / antagonists & inhibitors
-
Protein Isoforms / metabolism
-
Protein Kinase Inhibitors / chemistry*
-
Protein Kinase Inhibitors / pharmacokinetics
-
Protein Kinase Inhibitors / pharmacology*
-
Rats
-
Structure-Activity Relationship
-
beta Catenin / metabolism
Substances
-
Benzimidazoles
-
Protein Isoforms
-
Protein Kinase Inhibitors
-
beta Catenin
-
Casein Kinase I